Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) has been assigned a consensus rating of “Hold” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.40.
A number of research analysts recently commented on INO shares. StockNews.com began coverage on Inovio Pharmaceuticals in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research note on Wednesday, March 2nd. Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Friday, March 4th. Finally, Bank of America upgraded shares of Inovio Pharmaceuticals from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $8.00 to $10.00 in a report on Friday, January 21st. They noted that the move was a valuation call.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its holdings in Inovio Pharmaceuticals by 5.8% in the second quarter. Wells Fargo & Company MN now owns 126,883 shares of the biopharmaceutical company’s stock valued at $1,175,000 after purchasing an additional 6,971 shares during the period. Morgan Stanley boosted its stake in shares of Inovio Pharmaceuticals by 185.6% in the 2nd quarter. Morgan Stanley now owns 830,060 shares of the biopharmaceutical company’s stock valued at $7,694,000 after buying an additional 539,469 shares during the period. SG Americas Securities LLC grew its position in shares of Inovio Pharmaceuticals by 1,464.5% during the third quarter. SG Americas Securities LLC now owns 170,739 shares of the biopharmaceutical company’s stock worth $1,222,000 after buying an additional 159,826 shares in the last quarter. Raymond James & Associates increased its stake in shares of Inovio Pharmaceuticals by 41.2% during the third quarter. Raymond James & Associates now owns 31,921 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 9,307 shares during the period. Finally, Advisor Group Holdings Inc. raised its holdings in Inovio Pharmaceuticals by 26.4% in the third quarter. Advisor Group Holdings Inc. now owns 196,018 shares of the biopharmaceutical company’s stock valued at $1,401,000 after acquiring an additional 40,942 shares in the last quarter. Institutional investors and hedge funds own 43.28% of the company’s stock.
Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last released its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.17). Inovio Pharmaceuticals had a negative return on equity of 62.49% and a negative net margin of 17,104.84%. The company had revenue of $0.84 million for the quarter, compared to analyst estimates of $0.55 million. During the same period last year, the firm posted ($0.14) EPS. The business’s quarterly revenue was down 85.0% on a year-over-year basis. On average, sell-side analysts forecast that Inovio Pharmaceuticals will post -1.45 EPS for the current fiscal year.
Inovio Pharmaceuticals Company Profile (Get Rating)
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
- Get a free copy of the StockNews.com research report on Inovio Pharmaceuticals (INO)
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.